UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report: June 3, 2010
(Date of earliest event reported)
ABIOMED, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 04-2743260 | |
| (State or other Jurisdiction of Incorporation) |
(IRS Employer Identification Number) |
0-20584
(Commission File Number)
22 Cherry Hill Drive
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 777-5410
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e) On June 3, 2010, our compensation committee made its annual compensation determinations for our named executive officers. The committee determined the bonuses for fiscal 2010 performance, the salaries and target bonuses for fiscal 2011, and made the annual equity grants to executive officers. The compensation decisions made with respect to our executive officers who are serving as our principal executive officer, principal financial officer, or who were named executive officers in our most recent proxy statement were as follows:
| Executive Officer |
Fiscal 2010 Bonus |
Fiscal 2011 Salary |
Target Fiscal 2011 Bonus (Percentage of salary) |
Underlying Stock Options (4 year vesting) |
Underlying Restricted Stock (3 year vesting) |
Underlying Restricted Stock (Performance vesting) | |||||||||
| Michael R. Minogue, |
$ | 538,965 | $ | 405,153 | 100 | % | 105,000 | 53,000 | — | ||||||
| Robert L. Bowen, |
$ | 150,000 | $ | 295,800 | 50 | % | 30,000 | 20,000 | 12,000 | ||||||
| Andrew J. Greenfield, |
$ | 90,000 | $ | 221,450 | 45 | % | 25,000 | 15,000 | 10,000 | ||||||
| David Weber, |
$ | 165,000 | $ | 302,500 | 55 | % | 50,000 | 25,000 | 17,000 | ||||||
| William Bolt, |
$ | 120,000 | $ | 249,600 | 50 | % | 30,000 | 20,000 | 12,000 | ||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ABIOMED, Inc. | ||
| By: | /s/ ROBERT L. BOWEN | |
| Robert L. Bowen | ||
| Chief Financial Officer | ||
Date: June 9, 2010
3